In this CME-certified, on-demand Webcast of a CCO symposium at ASH 2019, a panel of experts discusses current management of β-thalassemia, the evolving role of biologic therapies changing the course of this disease, and the promise of gene therapy for a cure, including guidance on a series of patient cases and panel question and answer session.
Are you up to date on the current optimal management of β-thalassemia?
Are you prepared to use the newly approved erythroid maturation agent luspatercept in the care of your adult patients with transfusion-dependent β-thalassemia?
Read expert answers to key audience questions from a recent symposium on optimal management of patients with β-thalassemia.
Download this slideset for an expert-curated overview of emerging biological therapies for β-thalassemia, including review of the latest clinical data leading to the recent approval of the erythroid maturation agent luspatercept for transfusion-dependent disease.
Download this slideset for an expert-curated overview of gene therapy for β-thalassemia, including the latest clinical data that may soon change practice.
Download this slideset for an expert-curated overview of β-thalassemia, including genetics, pathophysiology, and conventional management strategies.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.